Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans
Anna Boronat,
Julian Mateus,
Natalia Soldevila-Domenech,
Mercè Guerra,
Jose Rodríguez-Morató,
Carlota Varon,
Daniel Muñoz,
Francina Barbosa,
Juan Carlos Morales,
Andreas Gaedigk,
Klaus Langohr,
Maria-Isabel Covas,
Clara Pérez-Mañá,
Montserrat Fitó,
Rachel F. Tyndale,
Rafael de la Torre
Affiliations
Anna Boronat
Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain
Julian Mateus
Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain
Natalia Soldevila-Domenech
Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain
Mercè Guerra
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain
Jose Rodríguez-Morató
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain
Carlota Varon
Department of Pharmacy, Vall d’Hebron Barcelona Hospital Campus, Passeig de Vall d’Hebron 119-129, 08035, Barcelona, Spain
Daniel Muñoz
Cardiovascular Risk and Nutrition Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003, Barcelona, Spain; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/028), Monforte de Lemos 3-5, 28029, Madrid, Spain
Department of Biochemistry and Molecular Pharmacology, Instituto de Parasitología y Biomedicina López Neyra, CSIC, PTS Granada, Avda. del Conocimiento, 17, 18016, Armilla, Granada, Spain
Andreas Gaedigk
Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, USA
Klaus Langohr
Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain; Department of Statistics and Operations Research, Polytechnic University of Catalonia, Barcelona, Spain
Maria-Isabel Covas
Cardiovascular Risk and Nutrition Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003, Barcelona, Spain; NUPROAS Handesbolag (NUPROAS HB), Nacka, Sweden
Clara Pérez-Mañá
School of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain; Hospital Universitari Germans Trias i Pujol (IGTP), Badalona, Spain
Montserrat Fitó
Cardiovascular Risk and Nutrition Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003, Barcelona, Spain; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/028), Monforte de Lemos 3-5, 28029, Madrid, Spain
Rachel F. Tyndale
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Departments of Pharmacology & Toxicology, and Psychiatry, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada
Rafael de la Torre
Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/028), Monforte de Lemos 3-5, 28029, Madrid, Spain; Corresponding author. Integrative Pharmacology and Systems Neuroscience Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article “Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial” [1]. Keywords: Tyrosol, Hydroxytyrosol, Endogenous conversion, CYP2A6, CYP2D6, Cardiovascular risk
